Status
Conditions
Treatments
About
Primary Objective: To document state-of- the-art multi-modality management of occluded biliary SEMS aiming to minimize number of reinterventions while providing symptom relief without procedure-related serious adverse events.
NOTE: This study will be hypothesis-generating for an anticipated randomized controlled study (RCT) to compare outcomes of placement of a plastic stent inside the occluded SEMS to outcomes of the proposed multi-modality approach.
Full description
Study Design:
Prospective, multi-center, single arm, post market, observational study
Two groups:
Primary Endpoint:
Successful restoration of bile duct drainage with biliary obstructive symptom and cholangitis relief as applicable, without procedure related SAE'S, from procedure through 30 days of follow-up.
Secondary Endpoints:
Occurrence and severity of procedure related serious adverse events from procedure through 30 days after procedure
Resolution of cholangitis where applicable
Technical success of procedure performed for restoration of bile duct drainage, overall and stratified by treatment group Sludge group: Ability to restore stent patency by cleaning the stent content followed by cholangiographically or cholangioscopically confirmed restored stent patency Ingrowth / overgrowth group: Ability to perform biliary radio frequency ablation (RFA) followed by cholangiographically or cholangioscopically confirmed restored stent patency
Improvement of biliary obstructive symptoms at 1 week and 1 month post procedure compared to Baseline
Improvement of Laboratory Liver Function Tests (LFT) at 1 week and 1 month post procedure compared to Baseline
Biliary Reintervention rate from procedure through 30 days after procedure, including reinterventions caused by plastic stent occlusion
Impact of cholangioscopy on current standard of care, which is to place a stent inside the occluded SEMS by
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
4 participants in 2 patient groups
Loading...
Central trial contact
Mohan Ramchandani, MD DM
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal